Please assess the completion status of the following clinical trial:

Trial Title: Electrical and Formocresol Pulpotomy in Primary Molars

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Restorable carious primary molars with reversible pulpitis and free of clinical or radiographic signs of pulp pathology~2. Males and females~3. Children ages 3-8 years old~4. Children classified under ASA I or II status~Exclusion Criteria:~1. Excluded will be primary molars with clinical or radiographic signs of pathology~2. Children not within age range~3. Absence of parent/caregiver~4. Mentally disabled parent/caregiver~5. Patients not returning for 6 month and 12 month follow up examination appointment

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 8 Years
- Healthy Volunteers: f

Study Arms:
- Formocresol (control) (Type: PLACEBO_COMPARATOR): This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Cotton pellets are saturated with conventional 1:5 dilution of Buckley's formocresol into the canal orifice for 5 minutes for complete hemostasis. IRM (Zinc Oxide Eugenol) cement will then be placed to seal the pulp chamber. A stainless steel crown will be cemented with Ketac Cement that was triturated for 10 seconds to complete the pulpotomy procedure and final restoration.
- Laser (Type: ACTIVE_COMPARATOR): This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Then a GENTLEray 980 Soft Tissue diode laser (Power: 3.0W, Mode: PW, Fiber: 300µm, Ton: 100ms, Toff: 100ms, Timer: cont) will be used to vaporize the residual pulp tissue and complete hemostasis. IRM (Zinc Oxide Eugenol) cement is then placed to seal the pulp chamber. A stainless steel crown cemented with Ketac Cement for the full coverage final restoration completes the pulpotomy procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).